Sickle Cell Disease
ICER will assess the comparative clinical effectiveness and value of treatments for sickle cell disease:
- Crizanlizumab (Novartis) is a P-selectin inhibitor
- Voxelotor (Global Blood Therapeutics) is an HbS polymerization inhibitor
- L-gluatmine, an amino acid approved for treatment of sickle cell disease
Date of review: March 2020
For questions, please contact Catherine Koola, Program Manager, at firstname.lastname@example.org.
The New England CEPAC will convene to deliberate and vote on evidence presented in ICER's report on treatments for sickle cell disease.